(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of 8.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.65%.
Mimedx Group's revenue in 2026 is $303,731,000.On average, 7 Wall Street analysts forecast MDXG's revenue for 2026 to be $37,527,684,237, with the lowest MDXG revenue forecast at $35,823,273,335, and the highest MDXG revenue forecast at $38,765,133,249. On average, 7 Wall Street analysts forecast MDXG's revenue for 2027 to be $44,616,749,448, with the lowest MDXG revenue forecast at $39,970,478,631, and the highest MDXG revenue forecast at $51,987,451,050.
In 2028, MDXG is forecast to generate $57,595,371,512 in revenue, with the lowest revenue forecast at $47,936,556,644 and the highest revenue forecast at $67,219,164,238.